Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Wants Comparative Effectiveness Studies on Long-Acting Anti-Psychotics

This article was originally published in The Pink Sheet Daily

Executive Summary

The Institute of Medicine's report on CE priorities, to be released June 30, may shape agenda across a number of product categories.

You may also be interested in...



J&J Takes Leaner, But Stronger Business Approach With Management Consolidation

The health care giant is eliminating some management positions with more organizational announcements expected in coming weeks.

J&J Takes Leaner, But Stronger Business Approach With Management Consolidation

The health care giant is eliminating some management positions with more organizational announcements expected in coming weeks.

J&J CNS Studies Show Awareness Of CER And Broader Databases

J&J's proposal to make long-acting anti-psychotic drugs a priority for the nation's push into comparative effectiveness research didn't make it onto the Institute of Medicine's "hot list" of research priorities released June 30 (1"The Pink Sheet" DAILY, June 30, 2009)

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel